Combined Treatment with Splenectomy and Cladribine in Hairy Cell Leukemia in Taiwan: A Clinicopathologic Study of 5 Cases
Autor: | Yuan-Bin Yu, Hui-Chi Hsu, Jie-Yu You, Chih-Cheng Chen, Wing-Keung Chau, Po-Ming Chen, Jyh-Pyng Gau, Chun-Yi Li, Chao-Hung Ho |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2007 |
Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment Splenectomy Antineoplastic Agents cladribine splenectomy medicine Humans hairy cell leukemia Hairy cell leukemia Cladribine Aged Medicine(all) Cytopenia Leukemia Hairy Cell lcsh:R5-920 business.industry General Medicine Middle Aged medicine.disease Pancytopenia Combined Modality Therapy Surgery Leukemia medicine.anatomical_structure Hairy Cell Female Bone marrow business lcsh:Medicine (General) medicine.drug |
Zdroj: | Journal of the Chinese Medical Association, Vol 70, Iss 12, Pp 551-555 (2007) |
ISSN: | 1726-4901 |
Popis: | Background Hairy cell leukemia (HCL) is a rare B-cell lymphoid malignancy that is characterized by the presence of hairy cells in the peripheral blood and bone marrow, pancytopenia and various degrees of splenomegaly. Very few reports have explored the clinicopathologic features and treatment outcome of HCL in Taiwan. Methods Of 33 patients with malignant lymphoma who underwent splenectomy over a 10-year period (1996–2005), 5 cases of HCL were retrospectively studied. Results All cases presented with various degrees of splenomegaly. Pancytopenia was noted in 3 cases, and lymphadenopathy in 1. Typical hairy cells with positive tartrate-resistant acid phosphatase stain were noted in 2 cases. Only 3 cases could be diagnosed with HCL based solely on bone marrow findings. In contrast, all spleen specimens had characteristic pathologic features. All patients underwent splenectomy uneventfully, and cladribine was given at a median time of 2 months after splenectomy without significant side effects. Complete remission with durable response was documented in 4 patients (80%) with a median follow-up of 29 months (range, 4–96 months). The last patient experienced partial remission but was only followed up for 4 months. Conclusion For the HCL patients in this study, splenectomy had a role not only in improving cytopenia but in aiding diagnosis. Cladribine is safe and highly effective for Taiwanese patients and should be considered as first-line treatment for HCL. |
Databáze: | OpenAIRE |
Externí odkaz: |